Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF REFINANCING OF FACILITY AGREEMENT

This announcement is made by Aceso Life Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to the announcements of the Company dated 16 April 2025, 14 July 2025 and 16 September 2025 (the "**Announcements**") in relation to the refinancing of the 2018 Facility Agreement. Unless otherwise stated, capitalized terms herein shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that all conditions precedent under the 2025 Facility Agreement have been fulfilled and completion has taken place on 26 September 2025. As a result of the completion, the total facility in the amount of approximately GBP87.3 million has been made available to the Company, of which approximately GBP70.3 million has been drawn down today for the purpose of full repayment of the UK Loan and the related transaction cost. The remaining GBP17 million will be used for capital expenditure on the UK Property in the upcoming one to two years. The Company will proceed with the planning of major refurbishments of the UK Property, including the upgrade of its major facilities and amenities in order to enhance the rental and capital value of the UK Property.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 26 September 2025

As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.